Made in Canada. Reborn in Sweden.
CCRM Nordic was created following a directive from the Swedish government to enhance the commercialization of advanced therapies. This effort is characterized by collaboration with significant partners from academia, industry, investors and healthcare in addition to ATMP specific initiatives. Together with TestaCenter and NorthX the aim is to improve the Swedish ecosystem.
Do you want to know more?
Modelled on the Highly Successful CCRM Concept
CCRM, founded in 2011, is a Canada-based collaboration between the public and private sector. CCRM is acknowledged as a leading center for regenerative medicine with achievements in both evolving and industrializing significant technologies. Collaborating with elite research entities and a worldwide industry consortium, CCRM effectively resolves major bottlenecks in the sector. CCRM Nordic follows the CCRM methodology, yet it is legally separate to CCRM Global.
Why We Exist
Driven by the ATMP 2030 project within the Vinnova-funded program Vision Driven Health, CCRM Nordic focuses on enabling the commercialization of ATMPs in Sweden, the Nordics and Europe.
Addressing Common Challenges
Addressing Common Challenges
Transitioning from lab to patient is complex, involving new regulatory requirements and standards like GMP. It also involves setting up and developing a profitable and attractive business model, built on a solid understanding of both the market and potential investors. We offer the specialized expertise and facilities needed to navigate these challenges.
Filling a Critical Need
Filling a Critical Need
Our current and future infrastructure offers crucial support for ATMP developers, addressing a vital gap in the Nordic innovation ecosystem. This effort is reinforced by targeted innovation programs and regional backing.
Advancing Medical Treatments
Advancing Medical Treatments
ATMPs offer new possibilities for treating diseases, a field where Swedish research excels. We aim to help transform this research into a steady flow of regenerative medicines ready for commercial production.